RxDoctor Payments Data

Kathryn Bradley, MD

Neuromuscular Medicine · Tucson, AZNPI 1073834362

Payments from drug & device makers

$2,024in general payments, 2019–2025

Across 110 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$972
  • Medtronic$281
  • Teva Pharmaceuticals USA, Inc.$156
  • Amneal Pharmaceuticals LLC$94
  • Boston Scientific$90
  • MDD US Operations, LLC$88
  • plus $343 from 10 others

What the payments were for

  • Speaking & faculty fees$181%
  • Food & beverage$1,84191%
  • Education$1658%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$281,047
Medicare patients
337
Services billed
17,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate57$409,400
RytaryCarbidopa/Levodopa168$218,338
AustedoDeutetrabenazine11$136,572
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5015$125,136
GocovriAmantadine Hcl33$104,620
NeuproRotigotine25$36,590
Carbidopa-LevodopaCarbidopa/Levodopa861$34,212
MyrbetriqMirabegron20$22,382
Carbidopa-Levodopa ErCarbidopa/Levodopa298$17,234
AmantadineAmantadine Hcl176$16,396
Rasagiline Mesylate74$16,169
GemtesaVibegron11$13,587
Entacapone19$9,464
Rivastigmine33$5,901
Memantine Hcl104$5,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$71$409,40057 claims
Amneal Pharmaceuticals LLCRytary$94$218,338168 claims
Teva Pharmaceuticals USA, Inc.Austedo$156$136,57211 claims
MDD US Operations, LLCGocovri$88$104,62033 claims
Almatica Pharma LLCSertraline Hcl$24$70396 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Tucson

Where these figures come from

Is this you, or does something look wrong? →